TELO TELOMIR PHARMA

NASDAQ
$0.42

TELOMIR PHARMA (TELO) is expected to report earnings on February 5, 2027, before the market open.

TELOMIR PHARMA Reported Earnings
Friday, November 6, 2026 · 12:00 AM ET
Earnings Date
Feb 5
Friday · Before Open
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TELOMIR PHARMA

Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE.

Charts powered in part by Lightweight Charts™ by TradingView.